Table 2.
Comparison of clinicopathological, radiological, and genetic characteristics according to histologic subtypes
| Variables | Non-mucinous AD (n = 442) |
Mucinous AD (n = 137) |
p value |
|---|---|---|---|
| Gender | 0.000b | ||
| Male | 233 (52.7) | 48 (35.0) | |
| Female | 209 (47.3) | 89 (65.0) | |
| Age (y) | 60.19 ± 9.53 | 58.87 ± 10.05 | 0.162a |
| Smoking | 0.023b | ||
| Never | 341 (77.1) | 118 (86.1) | |
| Past or current | 101 (22.9) | 19 (13.9) | |
| CEA | 0.003b | ||
| ≤ 2.24 | 216 (48.9) | 87 (63.5) | |
| >2.24 | 226 (51.1) | 50 (36.5) | |
| Emphysema | 0.000b | ||
| No | 331 (74.9) | 132 (96.4) | |
| Yes | 111 (25.1) | 5 (3.6) | |
| Distribution | 0.98b | ||
| Central | 12 (2.7) | 3 (2.2) | |
| Peripheral | 430 (97.3) | 134 (97.8) | |
| Location | 0.000b | ||
| Right upper lobe | 121 (27.4) | 21 (15.3) | |
| Right middle lobe | 50 (11.3) | 13 (9.5) | |
| Right lower lobe | 89 (20.1) | 41 (29.9) | |
| Left upper lobe | 101 (22.9) | 16 (11.7) | |
| Left lower lobe | 81 (18.3) | 46 (33.6) | |
| Diameter (cm) | 2.05 ± 0.64 | 2.21 ± 0.98 | 0.186a |
| CT value (HU) | 36.88 ± 15.7 | 20.89 ± 15.9 | 0.000a |
| Air bronchogram | 171 (38.7) | 100 (73.0) | 0.000b |
| Clinical T stage | 0.000b | ||
| T1a (≤ 1 cm) | 24 (5.4) | 21 (15.3) | |
| T1b (1–2 cm) | 205 (46.4) | 37 (27.0) | |
| T1c (2–3 cm) | 182 (41.2) | 41 (30.0) | |
| T2a (3–4 cm) | 31 (7.0) | 38 (27.7) | |
| Gene mutation | 303 (74.4) | 54 (68.3) | 0.26b |
| Mutation site | 0.000b | ||
| EGFR | 233 (57.2) | 4 (5.1) | |
| KRAS | 29 (7.1) | 37 (34.2) | |
| ALK | 35 (8.6) | 13 (16.5) | |
| Wild type | 104 (25.5) | 25 (31.6) | |
| Other | 6 (1.5) | 0 (0) | |
| Visceral pleural involvement | 93 (21.0) | 4 (2.9) | 0.000b |
| Lymphatic/vascular involvement | 17 (3.8) | 1 (0.73) | 0.12b |
| Pathological nodal involvement | 95 (21.5) | 12 (8.8) | 0.001b |
| Pathological stage | 0.000 b | ||
| IA1 | 23 (5.2) | 21 (15.3) | |
| IA2 | 131 (29.6) | 35 (25.5) | |
| IA3 | 110 (24.9) | 33 (24.1) | |
| IB | 79 (17.9) | 35 (25.5) | |
| IIA | 5 (1.1) | 1 (0.7) | |
| IIB | 32 (7.2) | 3 (2.2) | |
| IIIA | 62 (14.0) | 9 (6.6) | |
| Postoperative treatment | 202 (45.7) | 84 (61.3) | 0.001b |
| Overall recurrence | 170 (38.5) | 18 (13.1) | 0.000b |
| Cancer-related death | 79 (17.9) | 7 (5.1) | 0.000b |
Unless otherwise specified, data are numbers of patients, with percentages in parentheses. Percentages may not add up to 100 because of rounding.
AD adenocarcinoma, CEA carcinoembryonic antigen, HU Hounsfield unit, EGFR epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene, ALK anaplastic lymphoma kinase
a oneway analysis of variance (Wilcoxon W)
b chi-square test